Search

Author/Creator Liu, Dong-Geng

1. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Issue 4 (April 2015)

Authors:
Hu, Xi-Chun; Zhang, Jian; Xu, Bing-He; Cai, Li; Ragaz, Joseph; Wang, Zhong-Hua; Wang, Bi-Yun; Teng, Yue-E; Tong, Zhong-Sheng; Pan, Yue-Yin; Yin, Yong-Mei; Wu, Chang-Ping; Jiang, Ze-Fei; Wang, Xiao-Jia; Lou, Gu-Yin; Liu, Dong-Geng; Feng, Ji-Feng; Luo, Jian-Feng; Sun, Kang; Gu, Ya-Jia
Journal:
Lancet oncology
Issue:
Volume 16:Issue 4(2015:Apr.)
Page Start:
436
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Issue 4 (April 2015)

Authors:
Hu, Xi-Chun; Zhang, Jian; Xu, Bing-He; Cai, Li; Ragaz, Joseph; Wang, Zhong-Hua; Wang, Bi-Yun; Teng, Yue-E; Tong, Zhong-Sheng; Pan, Yue-Yin; Yin, Yong-Mei; Wu, Chang-Ping; Jiang, Ze-Fei; Wang, Xiao-Jia; Lou, Gu-Yin; Liu, Dong-Geng; Feng, Ji-Feng; Luo, Jian-Feng; Sun, Kang; Gu, Ya-Jia
Journal:
Lancet oncology
Issue:
Volume 16:Issue 4(2015:Apr.)
Page Start:
436
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search